BCAX

Bicara Therapeutics Inc. Health Care Pharmaceutical Preparations Russell 3000

$9.13Close $516.8MMarket cap $9.13 – $30.4052-week range Nov 9, 2026Next report

Highlights

Cautions

Not in an uptrend 1 of 8 trend conditions
Lagging the market RS 1 · weaker than 99% of stocks over 12 months
Far from its high 70% below its 52-week high
Distribution down-day volume 3.5× up-day volume over 50 sessions
Results soon Nov 9, 2026, in 8 days

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 11, 2026

Off 12-month high 70%

1wk 46.5% price change

1mo 50.9% price change

12-month return 45% market up 11% · its own down 53%

F-score — — Not assessed

Altman Z — Unknown

P/E — price / earnings

PEG — P/E / EPS growth

P/B 1.3× price / book

Earnings yield 37.0% EBIT / enterprise value

Cheaper than — of the market · not assessed

Revenue growth — year on year

EPS growth — latest quarter

Sales growth — latest quarter

ROE 31% return on equity

Free cash margin — -$107.1M FCF

D/E — long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Trade setup

ATR% 16.8% $1.53 a day · 2×ATR $6.06

RS 1 / 99 vs the universe

Trend 1 / 8 trend template

Relative volume 4.0× vs 50-day average

Up/down volume 0.29 50 sessions

Implied move — no option chain · report Nov 9, 2026

Trend template · 1 of 8

150-day average above the 200-day: passes

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged

Shareholders diluted The share count rose 4.0% over the year, from 54m to 57m shares. Each existing share owns a smaller fraction of the company than it did a year ago.

Last reported Aug 11, 2026

Last shock Oct 28, 2026-44% in one session15.6× volumeno filing matched-6% since

Financials

3 fiscal years · from filings

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$137.9M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$107.1M

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 56.60m +8738.5% since FY2023

	FY2023Dec 31, 2023	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Operating income	-$39.9M	-$82.4M	-$155.6M
Net income	-$52.0M	-$68.0M	-$137.9M
Earnings per share	-$0.09	-$0.00	-$0.00
Free cash flow	-$46.2M	-$74.8M	-$107.1M
Cash	$230.4M	$489.7M	$96.7M
Shareholders' equity	-$148.8M	$491.9M	$401.5M
Shares outstanding	640.39k	54.44m	56.60m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 11, 2026	Quarterly ↗	Jun 30, 2026	42d
May 11, 2026	Quarterly ↗	Mar 31, 2026	41d
Mar 30, 2026	Annual ↗	Dec 31, 2025	89d
Nov 10, 2025	Quarterly ↗	Sep 30, 2025	41d
Aug 12, 2025	Quarterly ↗	Jun 30, 2025	43d
May 13, 2025	Quarterly ↗	Mar 31, 2025	43d
Mar 27, 2025	Annual ↗	Dec 31, 2024	86d
Nov 12, 2024	Quarterly ↗	Sep 30, 2024	43d

Current reports

Filed	Disclosed
Aug 25, 2026	Material agreement ↗
Aug 11, 2026	Results ↗
Jul 28, 2026	Director or officer change · Regulation FD ↗
Jun 10, 2026	Shareholder vote ↗
May 21, 2026	Other events ↗
May 11, 2026	Results ↗
Mar 30, 2026	Results ↗
Feb 26, 2026	Material agreement · Results ↗
Feb 19, 2026	Other events ↗
Jan 12, 2026	Other events ↗
Dec 8, 2025	Regulation FD · Other events ↗
Nov 10, 2025	Results ↗